<DOC>
	<DOCNO>NCT00390468</DOCNO>
	<brief_summary>RATIONALE : Tandutinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well tandutinib work treat patient progressive prostate cancer bone metastasis .</brief_summary>
	<brief_title>Tandutinib Treating Patients With Progressive Prostate Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression patient progressive androgen-independent prostate cancer bone metastasis treat tandutinib . Secondary - Determine prostate-specific antigen ( PSA ) decline rate 50 % ( PSA response ) , use PSA Working Group Criteria , patient treat regimen . - Evaluate modulation bone pain bone marker patient treat regimen . - Determine objective tumor response RECIST ( Response Evaluation Criteria In Solid Tumors ) criterion patient treat regimen . - Determine qualitative quantitative toxicity regimen patient . OUTLINE : Patients receive oral tandutinib twice daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Bone pain assess baseline , day 1 course 3 , disease progression . After completion study treatment , patient follow 4 week . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm adenocarcinoma prostate . 2 . Patients must radiological evidence bone metastasis . 3 . Patients must castrate level testosterone ( &lt; /= 50ng/ml ) . For patient medically castrate , luteinizing hormone release hormone analog must continue maintain testicular suppression . 4 . Patients must evidence progressive disease ( e.g . progressive bone pain bone metastasis , increase bidimensional disease clinical examination Xrays appearance new lesion bone radiograph ) . Alternatively , patient without evidence progression , PSAprogression define 2 consecutive rise prostatespecific antigen ( PSA ) , absolute change least 1ng/ml , measure least 2 week apart . 5 . A minimum PSA &gt; /= 5ng/ml require . 6 . Patients antiandrogens discontinued therapy least 4 week ( bicalutamide least 6 week ) , unless interim evidence progression define Inclusion # 4 . 7 . Patients must one prior taxanebased regimen prior know PDGFR , plateletderived growth factor receptor , inhibitor ( e.g . imatinib , SU11248 , BAY439006 ) therapy permit . 8 . Age &gt; /= 18 year . Because dose adverse event data currently available use TANDUTINIB patient &lt; 18 year age , child exclude study . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 10 . Patients must adequate organ marrow function follow : leukocyte &gt; /= 3,000/mcL ; absolute neutrophil count &gt; /= 1,500/mcL ; platelet &gt; /= 100,000/mcL ; total bilirubin within normal institutional limit ; aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; /= 2.5 time institutional upper limit normal ; creatinine within normal institutional limit OR creatinine clearance &gt; /= 40 mL/min/1.73 m2 patient creatinine level institutional normal 11 . The effect TANDUTINIB develop human fetus recommend therapeutic dose unknown . For reason receptor tyrosine kinase inhibitor know teratogenic , men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry 3 month completion study therapy . 12 . Ability understand willingness sign write informed consent document . 13 . Men race ethnic group eligible trial . This study prostate cancer therefore applicable woman . 1 . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover doselimiting adverse event due agent administer 4 week earlier . 2 . Patients may receive investigational agent hormonal therapy besides use maintain medical castration . Glucocorticoid therapy intercurrent medical illness asthma , Chronic Obstructive Pulmonary Disease ( COPD ) rheumatoid arthritis flare allow . 3 . Patients may comedicated agent cause QTc prolongation . 4 . Patients mean QTc &gt; 500msec ( Bazett 's correction ) screen electrocardiogram history familial long QT syndrome ineligible . 5 . Left ventricular ejection fraction ( LVEF ) &lt; 40 % . 6 . Myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia . 7 . Ongoing vomiting , nausea &gt; /= Grade 2 ( National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 ) . If nausea , vomit control therapy ( therefore Grade 2 ) patient may enrol . 8 . Patients condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) impair ability swallow pill absorb oral medication exclude . 9 . History chronic liver disease . 10 . Known suspected primary muscular neuromuscular disease ( e.g. , muscular dystrophy , myasthenia gravis ) . 11 . History allergic reaction attribute compound similar chemical biologic composition tandutinib . Patients develop acneiform/maculopustular rash take either gefitinib erlotinib prevent receive tandutinib unless rash consider allergic reaction ( angioedema/urticaria ) StevensJohnson syndrome . 12 . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 13 . Uncontrolled intercurrent illness include , limited , ongoing active infection define require IV antibiotic Day 1 treatment psychiatric illness/social situation would limit compliance study requirement . 14 . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction TANDUTINIB . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Tandutinib</keyword>
	<keyword>MLN518</keyword>
	<keyword>CT53518</keyword>
	<keyword>pain</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>hormone-based castration</keyword>
</DOC>